电子邮件 | dav***@***.com | 获取Email |
---|
电子邮件 | dav***@***.com | 获取Email |
---|
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The US FDA has accepted for priority review Mesoblast's BLA to seek approval of RYONCIL to treat acute GVHD in children and set a PDUFA action date of September 30, 2020. The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast's approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing reviewof independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.
公司 | Mesoblast Limited |
---|---|
职位 | Director Clinical Development |
地点 | United States |
http://www.linkedin.com/in/david-j-n%c3%ba%c3%b1ez-27ab415 | |
部门 | |
头衔 | Director Clinical Development |
Mesoblast Limited Director Clinical Development
2021-07-01 -
Mesoblast Limited Clinical Liaison Director
2015-01-01 - 2021-07-01
Mesoblast Limited Director, Clinical Operations
2010-03-01 - 2015-01-01
Sr. Manager
2009-10-01 - 2010-02-01
Associate Director
2008-11-01 - 2009-10-01
David Nunez 在 Mesoblast Limited 担任 Director Clinical Development
David Nunez 在 Mesoblast Limited 的职位是 Director Clinical Development
David Nunez 的电子邮件地址是 dav***@***.com
David Nunez 的电话号码是 -
David Nunez 的公司电话号码是 +613****
David Nunez 在 research 工作。
David Nunez 的一些同事包括David Nunez、Maria Cabreira、Suman Abraham、Jenny ZafirisAndrew Chaponnel、。
David Nunez联系方式: 电子邮件地址:dav***@***.com 电话号码:-
David Nunez 的个人领英是:http://www.linkedin.com/in/david-j-n%c3%ba%c3%b1ez-27ab415
David Nunez 的办公地点:55 Collins Street, Level 38, Melbourne, Victoria, AU, 3000
Top-ranked on G2 Crowd
全球B2B企业库 海关贸易数据 展会采购数据
全球B2B企业库
海关贸易数据
展销采购数据
Top-ranked on G2 Crowd